最新发布
以资产优化和技术获取为核心，全球化工行业并购进入调整与复苏并行新阶段
近期，美国化工企业奥林与亨斯迈联合宣布，双方股东均以压倒性票数通过全股票合并方案，合并后的奥林—亨斯迈集团年营收预计达到125亿美元、市值突破120亿美元。2008年金融危机以来，全球化工行业并购先后经历两轮高峰，之后步入深度调整期。当前，…
印度SML考虑两到三年内上市，首个新分子即将面市
大农化网报道：印度农业投入品制造商SML Ltd（原Sulphur India Limited）正在评估未来两到三年内上市，以支持新化学实体（NCE）的开发。该公司董事总经理表示，目前尚未完全决定，公司仍在评估这一选项，预计在未来一到两年内…
Nichino Europe与Bi-PA联手，胆碱壬酸酯杀菌剂加速布局欧洲、中东和非洲
大农化网报道： Nichino Europe近日与比利时Bi-PA达成一项战略合作协议，根据该协议，Nichino Europe获得Bi-PA的产品TEMAP在欧洲、中东和非洲（EMEA）地区的全部知识产权。此次协议建立在双方长期合作的基础…
巴斯夫农业解决方案业务部与国际水稻研究所延续合作，进一步推动水稻可持续种植
第一阶段研究验证了降低水稻甲烷排放的可行方案 第二阶段将探索土壤健康、碳储存及生物炭应用 2026年9月9日，巴斯夫农业解决方案业务部与国际水稻研究所（IRRI）延续了双方名为″水稻温室气体减排优化项目″（OPTIMA Rice）的科研合作…
Digital ag platform xFarm Technologies expands to sugarcane, biofuels with Sibium Analytics acquisition
Swiss agtech company xFarm Technologies has acquired Brazilian agtech platform Sibium Analytics, which provides geospati…
dsm-firmenich and Estée Lauder advance AI-driven beauty discoveries
Beauty companies are increasingly shifting AI strategies from operational efficiency toward discovery and personalization. dsm-firmenich is applying AI to ingredient discovery through its partnership with Boltz, while The Estée Lauder Companies (ELC) is using AI-powered insights through Profound to optimize brand visibility across generative search platforms.
ResoTher heart data clear acquisition hurdle, set up 200-patient trial
Why it matters: RTP-026 is the first drug based on annexin A1, one of the body’s own brakes on inflammation, to be tested in heart attack patients. Three decades of trials to limit infarct size have been “disappointingly neutral,” an August review concluded.
Puig takes control of Isdin in US$1.4B dermocosmetics deal
Puig has agreed to acquire Corporación Químico-Farmacéutica Esteve’s remaining 50% interest in Isdin for €1.2 billion (US$1.41 billion), positioning the Spanish beauty group to take full control of the dermatology-focused skin care business.
Amorepacific microbiome extract targets post-acne pigmentation
Researchers at Amorepacific have identified a microbiome-derived culture extract that may address post-acne hyperpigmentation by targeting new melanin production and pigment already accumulated in the skin.
GSK returns to Chimagen for up to $750M myeloma trispecific
Why it matters: T-cell engagers have been highly effective in multiple myeloma but hard to tolerate, and GSK is buying a design meant to fix that. By binding T cells while targeting two validated tumor-associated antigens at once, the Chimagen molecule is intended to produce deeper and more durable responses than existing engagers with a better safety profile, which GSK says could open the class to broader adoption and earlier lines of treatment for the third most-common blood cancer globally. The prize it cites is a U.S. myeloma T-cell-engager market that external forecasts put above $10 billion by 2032.